Adaptive Treatment and Other Advances May Drive Radiotherapy Field Forward

Commentary
Video

Recent findings presented at ASTRO 2025 suggest an “exciting opportunity” to expand the role of radiation oncology in different nonmalignant indications.

In a discussion with CancerNetwork®, Louis Potters, MD, FASTRO, FABS, FACR, highlighted the next potential advances in radiation oncology that may improve outcomes for patients and drive the field forward. He spoke in the context of a new agreement between Lumonus and Northwell Health’s Smarter Radiation Oncology (SRO). Through this arrangement, collaborators seek to combine Lumonus’ artificial intelligence physician platform for streamlining administrative tasks with SRO’s consensus-based treatment protocols for optimizing the use of radiotherapy.

Potters, senior vice president, deputy physician in chief, and chair of the Department of Radiation Medicine at Northwell Health Cancer Institute and a radiation oncology editorial advisory board member for ONCOLOGY, noted the emergence of adaptive radiotherapy as a potential “paradigm change” in the specialty. Although the modality is still in its infancy, he stated that he is a “believer” in the efficiencies it may provide.

Additionally, Potters highlighted potential developments in the field based on research that was presented at the 2025 American Society of Radiation Oncology (ASTRO) Annual Meeting in San Francisco, California. Of note, he described how radiation medicine may have a growing role in nonmalignant indications such as osteoarthritis and cardiac arrhythmias.

Transcript:

Within radiation oncology, there is a huge number of initiatives that are exciting and driving the field forward. Outside of everything that we’ve just been talking about, the whole concept of adaptive radiation therapy and being able to plan patients based on their anatomy daily does represent a paradigm change for the specialty. We are still in its infancy in terms of being able to provide this service and understand the efficiencies associated with it, as well as the clinical outcomes. I’m a believer in that aspect going forward.

There are other things within radiation oncology, in the context of radiation medicine, coming out of the recent ASTRO meeting in terms of nonmalignant indications.... Between osteoarthritis, cardiac arrhythmias, and a host of other conditions, this represents an exciting opportunity going forward for the specialty.

Reference

Lumonus announces transformative multi-year licensing agreement with Smarter Radiation Oncology to bring evidenced-based directives to U.S. cancer centers. News release. Northwell Health; Lumonus. September 29, 2025. Accessed October 14, 2025. https://tinyurl.com/2s3wpsh7

Recent Videos
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
A collaboration between the Connecticut Departments of Health and Corrections and the COPPER Center aimed to improve outcomes among incarcerated patients.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Related Content